Free Trial
→ June 12: $100 Turns Into $100,000? (From Brownstone Research) (Ad)tc pixel Free SUPN Stock Alerts

Supernus Pharmaceuticals (SUPN) Financials

Supernus Pharmaceuticals logo
$48.21 0.00 (0.00%)
As of 05/22/2026 04:00 PM Eastern
Compare
Annual Income Statements for Supernus Pharmaceuticals

Annual Income Statements for Supernus Pharmaceuticals

This table shows Supernus Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 14 511 57 111 113 127 53 61 1.32 74 -39
Consolidated Net Income / (Loss)		 14 91 57 111 113 127 53 61 1.32 74 -39
Net Income / (Loss) Continuing Operations		 14 511 57 111 113 127 53 61 1.32 74 -39
Total Pre-Tax Income 		15 50 101 140 147 169 73 61 2.77 98 -49
Total Operating Income		 21 54 100 144 149 174 86 46 -5.27 82 -62
Total Gross Profit		 139 413 287 394 376 468 505 580 524 584 644
Total Revenue		 147 425 302 409 393 520 580 667 608 662 719
Operating Revenue		 147 425 302 409 393 520 580 667 608 662 719
Total Cost of Revenue		 8.42 12 15 15 17 52 75 87 84 78 75
Operating Cost of Revenue		 8.42 12 15 15 17 52 75 87 84 78 75
Total Operating Expenses		 118 -61 187 249 228 294 419 534 529 502 707
Selling, General & Admin Expense		 89 106 138 155 153 201 305 377 336 322 486
Research & Development Expense		 29 43 50 89 69 76 90 75 92 109 106
Amortization Expense		 - - - 5.19 5.18 16 30 83 82 78 89
Impairment Charge		 - - - - - - - 0.00 20 0.00 0.00
Other Special Charges / (Income)		 - - - 0.00 0.00 1.90 -6.53 -0.51 -1.52 -6.11 25
Total Other Income / (Expense), net		 -6.23 -3.85 1.08 -4.27 -1.08 -5.05 -13 15 8.04 16 13
Interest Expense		 7.11 5.76 - - - - - 7.07 2.42 0.00 0.00
Other Income / (Expense), net		 0.19 0.45 1.08 -4.27 -1.08 -5.05 -13 22 10 16 13
Income Tax Expense		 0.67 -41 43 29 34 42 20 0.03 1.45 24 -10
Basic Earnings per Share		 $0.29 $1.84 $1.13 $2.13 $2.16 $2.41 $1.01 $1.13 $0.02 $1.34 ($0.68)
Weighted Average Basic Shares Outstanding		 47.49M 49.47M 50.76M 51.99M 52.41M 52.62M 53.10M 53.67M 54.54M 55.10M 56.45M
Diluted Earnings per Share		 $0.28 $1.76 $1.08 $2.05 $2.10 $2.36 $0.98 $1.04 $0.02 $1.32 ($0.68)
Weighted Average Diluted Shares Outstanding		 51.16M 51.71M 53.30M 54.10M 53.82M 53.69M 54.36M 61.68M 55.51M 55.96M 56.45M
Weighted Average Basic & Diluted Shares Outstanding		 48.10M 49.60M 51.54M 52.32M 52.53M 52.92M 53.39M 54.38M - 55.81M 57.58M

Quarterly Income Statements for Supernus Pharmaceuticals

This table shows Supernus Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -16 1.18 0.12 20 38 15 -12 22 -45 -4.11 -2.29
Consolidated Net Income / (Loss)		 -16 1.18 0.12 20 38 15 -12 22 -45 -4.11 -2.29
Net Income / (Loss) Continuing Operations		 -16 1.18 0.12 20 38 15 -12 22 -45 -4.11 -2.29
Total Pre-Tax Income 		9.89 0.99 0.24 26 45 26 -5.83 17 -58 -1.91 -5.95
Total Operating Income		 8.14 -1.00 -3.15 23 41 21 -10 12 -60 -3.94 -8.33
Total Gross Profit		 134 145 127 150 158 148 134 149 173 189 184
Total Revenue		 154 164 144 168 176 174 150 165 192 212 208
Operating Revenue		 154 164 144 168 176 174 150 165 192 212 208
Total Cost of Revenue		 20 20 16 18 18 26 16 17 19 23 23
Operating Cost of Revenue		 20 20 16 18 18 26 16 17 19 23 23
Total Operating Expenses		 126 146 130 128 117 127 144 136 233 193 193
Selling, General & Admin Expense		 83 81 87 86 70 79 90 94 180 122 125
Research & Development Expense		 23 23 25 26 29 29 27 22 29 28 39
Amortization Expense		 21 21 20 20 19 18 20 21 24 25 26
Other Special Charges / (Income)		 -0.46 -0.20 -1.10 -4.36 -1.02 0.36 7.66 0.00 0.00 18 2.39
Total Other Income / (Expense), net		 1.75 1.99 3.40 3.73 4.10 4.98 4.43 4.53 2.28 2.02 2.38
Other Income / (Expense), net		 1.75 1.99 3.40 3.73 4.10 4.98 4.43 4.53 2.28 2.02 2.38
Income Tax Expense		 26 -0.19 0.12 6.39 6.45 11 6.00 -5.83 -13 2.19 -3.66
Basic Earnings per Share		 ($0.29) $0.02 $0.00 $0.36 $0.70 $0.28 ($0.21) $0.40 ($0.80) ($0.07) ($0.04)
Weighted Average Basic Shares Outstanding		 54.61M 54.54M 54.80M 54.98M 55.15M 55.10M 55.86M 56.02M 56.55M 56.45M 57.65M
Diluted Earnings per Share		 ($0.29) $0.04 $0.00 $0.36 $0.69 $0.27 ($0.21) $0.40 ($0.80) ($0.07) ($0.04)
Weighted Average Diluted Shares Outstanding		 54.61M 55.51M 55.63M 55.72M 56.02M 55.96M 55.86M 56.64M 56.55M 56.45M 57.65M
Weighted Average Basic & Diluted Shares Outstanding		 54.63M 0.00 54.97M 55.11M 55.22M 55.81M 55.99M 56.07M 57.34M 57.58M 58.04M

Annual Cash Flow Statements for Supernus Pharmaceuticals

This table details how cash moves in and out of Supernus Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -2.90 -58 34 92 -11 107 -85 -110 -18 -5.72 61
Net Cash From Operating Activities		 35 67 115 129 143 138 127 117 111 172 47
Net Cash From Continuing Operating Activities		 35 -24 115 129 143 138 127 117 111 172 47
Net Income / (Loss) Continuing Operations		 14 0.00 57 111 113 127 53 61 1.32 74 -39
Consolidated Net Income / (Loss)		 14 - 57 111 113 127 53 61 1.32 74 -39
Depreciation Expense		 0.92 2.40 8.13 7.06 6.66 18 33 86 85 80 92
Amortization Expense		 0.75 0.52 -0.51 10 12 14 18 5.35 0.41 1.82 -1.53
Non-Cash Adjustments To Reconcile Net Income		 25 22 31 48 17 14 31 16 61 59 40
Changes in Operating Assets and Liabilities, net		 -6.35 -49 18 -48 -5.03 -34 -7.95 -51 -36 -43 -45
Net Cash From Investing Activities		 -39 -36 -86 -413 -158 -35 -82 -217 269 -190 4.11
Net Cash From Continuing Investing Activities		 -39 -36 -86 -413 -158 -35 -82 -217 269 -190 4.11
Purchase of Property, Plant & Equipment		 -2.10 -1.60 -2.03 -0.84 -1.39 -3.69 -2.05 -0.41 -0.55 -0.73 -1.34
Acquisitions		 -11 -19 -11 0.00 0.00 -299 -312 - 0.00 0.00 -293
Purchase of Investments		 -64 -47 -102 -492 -410 -96 -312 -407 -102 -688 -476
Sale and/or Maturity of Investments		 38 32 29 80 253 378 531 191 371 499 774
Net Cash From Financing Activities		 1.87 2.05 5.68 376 3.93 3.56 -130 -10 -398 12 9.13
Net Cash From Continuing Financing Activities		 1.87 2.05 5.68 376 3.93 3.56 -130 -10 -398 12 9.13
Repayment of Debt		 - - - - 0.00 0.00 -138 0.00 -496 0.00 0.00
Issuance of Debt		 - - 0.00 403 - - - 0.00 93 0.00 0.00
Issuance of Common Equity		 1.87 2.05 5.68 77 3.93 4.36 7.10 12 6.61 15 38
Other Financing Activities, net		 - - 0.00 -93 0.00 -0.80 0.80 -23 -1.99 -2.72 -28
Cash Interest Paid		 0.83 0.49 0.13 1.34 2.52 2.52 2.52 2.52 1.95 0.00 0.00
Cash Income Taxes Paid		 - - 1.59 35 52 45 25 16 37 53 16

Quarterly Cash Flow Statements for Supernus Pharmaceuticals

This table details how cash moves in and out of Supernus Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 70 -20 -12 -11 -20 38 47 29 8.11 -23 56
Net Cash From Operating Activities		 36 45 38 36 54 44 31 59 -62 20 67
Net Cash From Continuing Operating Activities		 36 45 38 36 54 44 31 59 -62 20 67
Net Income / (Loss) Continuing Operations		 -16 1.18 0.12 20 38 15 -12 22 -45 -4.11 -2.29
Consolidated Net Income / (Loss)		 -16 1.18 0.12 20 38 15 -12 22 -45 -4.11 -2.29
Depreciation Expense		 22 22 21 21 20 19 20 21 25 25 26
Amortization Expense		 0.07 0.73 1.89 -0.36 0.97 -0.67 -1.07 -0.03 -0.92 0.50 -0.19
Non-Cash Adjustments To Reconcile Net Income		 9.98 30 21 11 24 15 6.97 5.48 11 13 13
Changes in Operating Assets and Liabilities, net		 20 -8.69 -5.66 -15 -30 -4.43 16 9.23 -52 -15 30
Net Cash From Investing Activities		 35 -66 -52 -49 -77 -13 37 -31 49 -51 -19
Net Cash From Continuing Investing Activities		 35 -66 -52 -49 -77 -13 37 -31 49 -51 -19
Purchase of Property, Plant & Equipment		 -0.15 0.04 -0.25 -0.06 -0.20 -0.21 -0.33 -0.46 -0.13 -0.43 0.00
Purchase of Investments		 - -102 -194 -124 -225 -145 -119 -141 -127 -90 -78
Sale and/or Maturity of Investments		 35 36 142 75 148 133 156 110 469 39 59
Net Cash From Financing Activities		 -0.23 1.09 1.57 1.66 3.08 5.89 -21 0.94 21 8.53 9.12
Net Cash From Continuing Financing Activities		 -0.23 1.09 1.57 1.66 3.08 5.89 -21 0.94 21 8.53 9.12
Issuance of Common Equity		 0.74 1.09 2.91 1.66 3.46 6.88 2.04 3.28 24 8.56 14
Other Financing Activities, net		 -0.97 - -1.34 -0.00 -0.39 -0.99 -23 -2.34 -2.67 -0.03 -4.56
Cash Income Taxes Paid		 6.62 9.55 0.34 20 20 13 0.27 12 3.08 0.27 -0.41

Annual Balance Sheets for Supernus Pharmaceuticals

This table presents Supernus Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 189 310 424 978 1,160 1,504 1,689 1,703 1,278 1,368 1,453
Total Current Assets		 106 151 228 493 473 630 602 734 493 686 644
Cash & Equivalents		 33 66 100 192 181 289 203 93 75 69 128
Short-Term Investments		 29 24 40 164 166 134 136 368 180 384 180
Accounts Receivable		 26 42 66 103 87 141 149 165 144 142 188
Inventories, net		 13 17 16 26 27 48 86 92 77 54 82
Prepaid Expenses		 5.26 2.96 6.52 8.89 12 19 27 16 17 36 65
Plant, Property, & Equipment, net		 3.87 4.34 5.12 4.10 17 0.00 0.00 15 14 12 11
Total Noncurrent Assets		 79 154 191 480 671 874 1,088 953 771 670 798
Goodwill		 - - - - 0.00 78 118 117 117 117 125
Intangible Assets		 0.98 36 36 31 25 364 785 702 600 522 569
Noncurrent Deferred & Refundable Income Taxes		 - 42 21 30 32 - - - - 0.00 38
Other Noncurrent Operating Assets		 23 0.33 0.39 0.38 22 81 66 40 38 32 65
Total Liabilities & Shareholders' Equity		 189 310 424 978 1,160 1,504 1,689 1,703 1,278 1,368 1,453
Total Liabilities		 101 118 157 525 565 759 873 816 356 332 391
Total Current Liabilities		 57 81 123 161 161 245 315 688 290 292 338
Short-Term Debt		 - - - - 0.00 31 45 423 52 47 31
Accounts Payable		 4.31 8.06 6.84 40 50 79 118 96 80 76 108
Accrued Expenses		 52 69 96 107 108 126 133 152 154 169 161
Other Current Liabilities		 0.50 3.10 4.28 2.18 3.24 9.08 20 17 4.28 0.00 38
Total Noncurrent Liabilities		 44 37 34 363 404 514 558 128 66 40 53
Other Noncurrent Operating Liabilities		 35 31 33 34 59 89 52 79 41 35 53
Commitments & Contingencies		 - - - - - - - - 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 88 192 267 453 595 745 816 886 922 1,036 1,062
Total Preferred & Common Equity		 88 192 267 453 595 745 816 886 922 1,036 1,062
Total Common Equity		 88 192 267 453 595 745 816 886 922 1,036 1,062
Common Stock		 264 276 295 370 388 409 434 408 440 479 544
Retained Earnings		 -176 -84 -27 86 200 326 380 481 483 556 518
Accumulated Other Comprehensive Income / (Loss)		 -0.49 -0.13 -0.75 -3.16 7.42 8.98 1.54 -3.21 -0.59 -0.19 -0.04

Quarterly Balance Sheets for Supernus Pharmaceuticals

This table presents Supernus Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 1,693 1,792 1,293 1,285 1,304 1,316 1,343 1,347 1,382 1,420 1,501
Total Current Assets		 664 883 424 449 544 591 640 688 739 594 732
Cash & Equivalents		 111 58 25 95 63 52 32 116 145 151 185
Short-Term Investments		 280 170 127 105 234 295 372 348 378 130 199
Accounts Receivable		 164 144 137 142 148 152 145 146 141 171 182
Inventories, net		 83 91 91 83 75 68 64 49 44 79 87
Prepaid Expenses		 25 16 45 24 24 23 27 29 31 62 78
Plant, Property, & Equipment, net		 0.00 15 14 14 13 12 12 11 11 11 10
Total Noncurrent Assets		 1,029 894 855 822 747 713 691 648 632 815 759
Goodwill		 117 117 117 117 117 117 117 117 117 119 121
Intangible Assets		 723 682 662 641 580 560 540 502 481 623 550
Noncurrent Deferred & Refundable Income Taxes		 - - - - - - - - 6.18 8.79 31
Other Noncurrent Operating Assets		 57 40 38 39 38 36 34 29 28 64 58
Total Liabilities & Shareholders' Equity		 1,693 1,792 1,293 1,285 1,304 1,316 1,343 1,347 1,382 1,420 1,501
Total Liabilities		 840 880 373 373 375 358 336 317 319 370 424
Total Current Liabilities		 726 732 253 288 315 309 292 282 286 331 374
Short-Term Debt		 449 481 21 46 51 47 47 30 0.00 11 0.00
Accounts Payable		 110 95 83 78 86 83 76 77 78 109 101
Accrued Expenses		 158 148 149 162 167 175 169 170 181 184 190
Other Current Liabilities		 8.19 7.49 0.00 0.71 9.55 3.62 0.00 4.75 28 26 83
Total Noncurrent Liabilities		 114 148 121 85 60 50 44 35 32 39 50
Other Noncurrent Operating Liabilities		 56 98 76 50 41 38 37 34 32 39 50
Commitments & Contingencies		 - - - - 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 853 912 920 912 929 957 1,007 1,031 1,064 1,050 1,077
Total Preferred & Common Equity		 853 912 920 912 929 957 1,007 1,031 1,064 1,050 1,077
Total Common Equity		 853 912 920 912 929 957 1,007 1,031 1,064 1,050 1,077
Common Stock		 401 416 424 432 447 455 466 486 497 528 561
Retained Earnings		 456 498 497 481 483 503 541 545 567 522 516
Accumulated Other Comprehensive Income / (Loss)		 -4.05 -2.33 -1.78 -1.21 -0.53 -0.37 0.08 -0.16 -0.20 -0.07 -0.26

Annual Metrics And Ratios for Supernus Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Supernus Pharmaceuticals' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 - - - - - - - - - - 57,339,350.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 57,339,350.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - -0.67
Growth Metrics		 - - - - - - - - - - -
Profitability Metrics		 - - - - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 20 98 57 114 114 131 63 46 -2.50 62 -44
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - 3.52% -0.26% 5.69% -3.99%
Earnings before Interest and Taxes (EBIT)		 21 55 101 140 147 169 73 68 5.18 98 -49
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 23 58 108 157 166 200 124 159 90 180 41
Valuation Ratios		 - - - - - - - - - - -
Leverage & Solvency		 - - - - - - - - - - -
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 15 46 93 101 120 -261 -366 114 49 134 -198
Efficiency Ratios		 - - - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -22 30 -6.20 7.67 1.75 393 822 754 702 629 784
Increase / (Decrease) in Invested Capital		 5.12 52 -37 14 -5.92 391 429 -68 -52 -73 155
Book Value per Share		 $1.80 $3.87 $5.22 $8.67 $11.35 $14.14 $15.34 $16.39 $16.87 $18.76 $18.52
Tangible Book Value per Share		 $1.78 $3.14 $4.52 $8.07 $10.88 $5.74 ($1.62) $1.23 $3.75 $7.19 $6.41
Total Capital		 95 196 267 782 941 1,166 1,281 1,309 974 1,083 1,093
Total Debt		 7.09 4.17 0.00 329 345 421 465 423 52 47 31
Total Long-Term Debt		 7.09 4.17 0.00 329 345 390 421 0.00 0.00 0.00 0.00
Net Debt		 -110 -161 -274 -445 -594 -352 6.54 -132 -219 -406 -278
Capital Expenditures (CapEx)		 2.10 1.60 2.03 0.84 1.39 3.69 2.05 0.41 0.55 0.73 1.34
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -13 -19 -35 -24 -35 -6.32 -8.63 7.95 0.11 -13 28
Debt-free Net Working Capital (DFNWC)		 49 71 105 332 312 416 331 469 255 441 337
Net Working Capital (NWC)		 49 71 105 332 312 385 286 46 203 394 306
Net Nonoperating Expense (NNE)		 5.95 6.97 -0.61 3.38 0.83 3.80 9.38 -15 -3.82 -12 -5.05
Net Nonoperating Obligations (NNO)		 -110 -161 -274 -445 -594 -352 6.54 -132 -219 -406 -278
Total Depreciation and Amortization (D&A)		 1.67 2.92 7.62 17 18 32 51 91 85 82 90
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.30 $1.84 $1.13 $2.13 $2.16 $2.41 $1.01 $1.13 $0.00 $1.34 ($0.68)
Adjusted Weighted Average Basic Shares Outstanding		 47.49M 49.47M 50.76M 51.99M 52.41M 52.62M 53.10M 53.67M 0.00 55.10M 56.45M
Adjusted Diluted Earnings per Share		 $0.28 $1.76 $1.08 $2.05 $2.10 $2.36 $0.98 $1.04 $0.00 $1.32 ($0.68)
Adjusted Weighted Average Diluted Shares Outstanding		 51.16M 51.71M 53.30M 54.10M 53.82M 53.69M 54.36M 61.68M 0.00 55.96M 56.45M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $2.16 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 49.40M 50.16M 51.54M 52.32M 52.53M 52.92M 53.39M 54.38M 0.00 55.81M 57.58M
Normalized Net Operating Profit after Tax (NOPAT)		 20 38 57 114 114 132 58 46 9.38 57 -26
Debt Service Ratios		 - - - - - - - - - - -
Payout Ratios		 - - - - - - - - - - -

Quarterly Metrics And Ratios for Supernus Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Supernus Pharmaceuticals' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - - 57,339,350.00 57,581,712.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - 57,339,350.00 57,581,712.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - -0.07 -0.04
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -13.24% -1.80% -6.58% 24.17% 14.17% 5.99% 4.30% -1.71% 9.34% - 38.63%
EBITDA Growth		 23.64% -59.76% -25.21% 904.02% 107.49% 90.45% -41.11% -18.57% -151.61% - 48.32%
EBIT Growth		 672.58% -97.30% -97.69% 262.19% 354.47% 2,564.85% -2,499.59% -36.62% -228.95% - -2.04%
NOPAT Growth		 -1,133.21% -104.75% -116.54% 238.81% 366.12% 1,152.04% -346.21% -4.11% -220.51% - 18.76%
Net Income Growth		 -1,013.44% -95.39% -99.27% 2,496.63% 340.97% 1,204.51% -9,637.90% 12.97% -217.20% - 80.61%
EPS Growth		 -1,066.67% -90.91% -100.00% 1,900.00% 337.93% 575.00% 0.00% 11.11% -215.94% - 80.95%
Operating Cash Flow Growth		 159.19% 63.10% -21.83% 288.75% 49.18% -1.23% -20.32% 64.31% -215.22% - 117.41%
Free Cash Flow Firm Growth		 107.67% -45.53% -76.11% 530.11% 264.09% 67.51% 97.94% 19.49% -246.20% - -251.50%
Invested Capital Growth		 -5.83% -6.89% -5.01% -12.50% -11.22% -10.35% -11.03% -17.68% 19.86% - 15.99%
Revenue Q/Q Growth		 13.51% 6.78% 0.00% 17.18% 4.37% -0.87% -13.97% 10.43% 16.11% - -1.83%
EBITDA Q/Q Growth		 584.61% -26.47% 0.00% 103.87% 41.48% -32.51% -69.75% 181.90% -189.67% - -15.30%
EBIT Q/Q Growth		 160.98% -89.99% 0.00% 10,723.87% 70.87% -41.30% -122.10% 385.87% -447.68% - -210.87%
NOPAT Q/Q Growth		 -6.79% 91.01% 0.00% 1,162.15% 104.73% -64.45% -157.73% 328.26% -357.28% - -111.63%
Net Income Q/Q Growth		 -1,822.50% 107.35% 0.00% 15,961.29% 93.30% -60.18% -177.16% 290.23% -300.53% - 44.14%
EPS Q/Q Growth		 -1,350.00% 113.79% 0.00% 0.00% 91.67% -60.87% -177.78% 290.48% -300.00% - 42.86%
Operating Cash Flow Q/Q Growth		 290.08% 25.32% 0.00% -7.23% 50.24% -17.03% -31.09% 91.30% -205.35% - 234.95%
Free Cash Flow Firm Q/Q Growth		 82.74% 57.74% 0.00% 228.69% 5.59% -27.43% -21.41% 98.43% -229.20% - 35.65%
Invested Capital Q/Q Growth		 -2.49% -4.18% 0.00% -2.02% -1.07% -3.24% -5.14% -9.35% 44.05% - -11.67%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 87.26% 88.06% 88.65% 89.36% 89.99% 85.01% 89.48% 89.83% 90.13% - 88.74%
EBITDA Margin		 20.67% 14.24% 15.93% 27.72% 37.57% 25.58% 9.00% 22.96% -17.73% - 9.62%
Operating Margin		 5.29% -0.61% -2.20% 13.41% 23.25% 12.29% -6.85% 7.34% -31.35% - -4.01%
EBIT Margin		 6.43% 0.60% 0.17% 15.63% 25.58% 15.15% -3.89% 10.07% -30.17% - -2.86%
Profit (Net Income) Margin		 -10.38% 0.72% 0.09% 11.83% 21.91% 8.80% -7.89% 13.60% -23.49% - -1.10%
Tax Burden Percent		 -161.55% 118.69% 51.03% 75.72% 85.66% 58.10% 202.83% 134.98% 77.85% - 38.54%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00%
Effective Tax Rate		 261.55% -18.69% 48.97% 24.28% 14.34% 41.90% 0.00% -34.98% 0.00% - 0.00%
Return on Invested Capital (ROIC)		 -6.91% -0.60% 0.00% 0.00% 0.00% 7.10% -5.05% 10.99% -20.92% - -3.38%
ROIC Less NNEP Spread (ROIC-NNEP)		 -4.68% -1.94% 0.00% 0.00% 0.00% 6.17% -3.70% 9.50% -19.97% - -4.25%
Return on Net Nonoperating Assets (RNNOA)		 0.67% 0.38% 0.00% 0.00% 0.00% -1.97% 1.31% -3.87% 6.08% - 1.65%
Return on Equity (ROE)		 -6.23% -0.22% 0.00% 0.00% 0.00% 5.12% -3.74% 7.12% -14.83% - -1.73%
Cash Return on Invested Capital (CROIC)		 8.76% 6.79% 5.14% 13.33% 11.89% 20.17% 19.61% 27.79% -21.69% - -21.35%
Operating Return on Assets (OROA)		 2.63% 0.25% 0.00% 0.00% 0.00% 7.58% -1.96% 4.97% -14.89% - -1.56%
Return on Assets (ROA)		 -4.26% 0.29% 0.00% 0.00% 0.00% 4.40% -3.98% 6.70% -11.59% - -0.60%
Return on Common Equity (ROCE)		 -6.23% -0.22% 0.00% 0.00% 0.00% 5.12% -3.74% 7.12% -14.83% - -1.73%
Return on Equity Simple (ROE_SIMPLE)		 2.81% 0.00% 0.00% 0.00% 0.00% 0.00% 6.01% 0.00% 0.00% - 0.00%
Net Operating Profit after Tax (NOPAT)		 -13 -1.18 -1.61 17 35 12 -7.18 16 -42 -2.76 -5.83
NOPAT Margin		 -8.54% -0.72% -1.12% 10.15% 19.91% 7.14% -4.79% 9.90% -21.95% - -2.81%
Net Nonoperating Expense Percent (NNEP)		 -2.23% 1.34% 0.75% 1.21% 1.31% 0.92% -1.34% 1.49% -0.94% - 0.87%
Return On Investment Capital (ROIC_SIMPLE)		 - -0.12% - - - 1.15% -0.68% 1.54% -3.97% -0.25% -0.54%
Cost of Revenue to Revenue		 12.74% 11.94% 11.35% 10.64% 10.01% 14.99% 10.52% 10.17% 9.87% - 11.26%
SG&A Expenses to Revenue		 53.74% 49.47% 60.23% 51.03% 39.70% 45.60% 60.03% 56.54% 93.53% - 60.26%
R&D to Revenue		 14.72% 14.21% 17.36% 15.56% 16.53% 16.45% 17.97% 13.37% 15.29% - 18.99%
Operating Expenses to Revenue		 81.97% 88.66% 90.84% 75.95% 66.74% 72.72% 96.32% 82.49% 121.48% - 92.75%
Earnings before Interest and Taxes (EBIT)		 9.89 0.99 0.24 26 45 26 -5.83 17 -58 -1.91 -5.95
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 32 23 23 47 66 45 13 38 -34 24 20
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.65 1.72 2.01 1.54 1.71 1.93 1.77 1.66 2.55 - 2.76
Price to Tangible Book Value (P/TBV)		 9.77 7.73 8.02 5.24 4.91 5.03 4.44 3.79 8.73 - 7.32
Price to Revenue (P/Rev)		 2.47 2.60 0.00 0.00 0.00 3.02 2.74 2.65 3.93 - 3.83
Price to Earnings (P/E)		 58.75 1,201.42 0.00 0.00 0.00 27.03 29.52 27.36 0.00 - 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings Yield		 1.70% 0.08% 0.00% 0.00% 0.00% 3.70% 3.39% 3.65% 0.00% - 0.00%
Enterprise Value to Invested Capital (EV/IC)		 1.81 1.94 2.39 1.78 2.09 2.53 2.34 2.29 3.09 - 3.74
Enterprise Value to Revenue (EV/Rev)		 2.17 2.24 0.00 0.00 0.00 2.40 2.09 1.87 3.54 - 3.34
Enterprise Value to EBITDA (EV/EBITDA)		 11.22 15.05 0.00 0.00 0.00 8.83 8.17 7.67 38.89 - 54.55
Enterprise Value to EBIT (EV/EBIT)		 39.16 262.66 0.00 0.00 0.00 16.25 15.19 15.12 0.00 - 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 63.55 0.00 0.00 0.00 0.00 25.80 27.73 24.67 0.00 - 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 14.15 12.26 0.00 0.00 0.00 9.25 8.49 6.64 33.53 - 31.13
Enterprise Value to Free Cash Flow (EV/FCFF)		 20.02 27.53 45.38 12.46 16.56 11.85 11.22 7.46 0.00 - 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.05 0.06 0.06 0.05 0.05 0.05 0.03 0.00 0.01 - 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Financial Leverage		 -0.14 -0.19 -0.25 -0.25 -0.28 -0.32 -0.35 -0.41 -0.30 - -0.39
Leverage Ratio		 1.69 1.65 1.68 1.39 1.37 1.35 1.35 1.33 1.34 - 1.35
Compound Leverage Factor		 1.69 1.65 1.68 1.39 1.37 1.35 1.35 1.33 1.34 - 1.35
Debt to Total Capital		 4.79% 5.35% 5.24% 4.71% 4.42% 4.37% 2.83% 0.00% 1.06% - 0.00%
Short-Term Debt to Total Capital		 4.79% 5.35% 5.24% 4.71% 4.42% 4.37% 2.83% 0.00% 1.06% - 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Common Equity to Total Capital		 95.21% 94.65% 94.76% 95.29% 95.58% 95.63% 97.17% 100.00% 98.94% - 100.00%
Debt to EBITDA		 0.39 0.58 0.00 0.00 0.00 0.26 0.18 0.00 0.18 - 0.00
Net Debt to EBITDA		 -1.52 -2.43 0.00 0.00 0.00 -2.26 -2.54 0.00 -4.36 - 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Debt to NOPAT		 2.20 -20.79 0.00 0.00 0.00 0.77 0.60 0.00 -0.43 - 0.00
Net Debt to NOPAT		 -8.60 87.62 0.00 0.00 0.00 -6.59 -8.62 0.00 10.44 - 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Altman Z-Score		 3.60 3.86 3.71 3.32 4.06 5.07 4.87 4.81 5.43 - 5.48
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.56 1.70 1.73 1.91 2.20 2.35 2.44 2.58 1.80 - 1.96
Quick Ratio		 1.19 1.38 1.42 1.62 1.88 2.04 2.16 2.32 1.37 - 1.51
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 32 51 34 111 117 85 67 133 -171 -157 -101
Operating Cash Flow to CapEx		 23,916.67% 0.00% 15,484.27% 55,662.50% 26,760.00% 20,847.89% 9,357.49% 12,864.84% -47,801.55% - 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.41 0.41 0.00 0.00 0.00 0.50 0.50 0.49 0.49 - 0.55
Accounts Receivable Turnover		 3.99 3.92 0.00 0.00 0.00 4.62 4.55 4.54 4.30 - 4.74
Inventory Turnover		 1.05 0.99 0.00 0.00 0.00 1.18 1.24 1.36 1.08 - 1.20
Fixed Asset Turnover		 0.00 42.33 0.00 0.00 0.00 52.79 54.96 56.99 60.57 - 72.67
Accounts Payable Turnover		 0.92 0.95 0.00 0.00 0.00 1.00 0.95 0.95 0.84 - 0.92
Days Sales Outstanding (DSO)		 91.42 93.02 0.00 0.00 0.00 78.93 80.15 80.48 84.79 - 77.01
Days Inventory Outstanding (DIO)		 349.15 368.03 0.00 0.00 0.00 308.52 293.71 268.42 336.97 - 303.06
Days Payable Outstanding (DPO)		 395.51 383.20 0.00 0.00 0.00 365.26 385.22 383.68 433.41 - 395.54
Cash Conversion Cycle (CCC)		 45.06 77.85 0.00 0.00 0.00 22.19 -11.36 -34.78 -11.65 - -15.47
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 733 702 671 658 651 629 597 541 780 784 693
Invested Capital Turnover		 0.81 0.83 0.00 0.00 0.00 0.99 1.05 1.11 0.95 - 1.20
Increase / (Decrease) in Invested Capital		 -45 -52 -35 -94 -82 -73 -74 -116 129 155 95
Enterprise Value (EV)		 1,326 1,362 1,606 1,171 1,362 1,590 1,394 1,242 2,410 - 2,592
Market Capitalization		 1,505 1,581 1,864 1,471 1,718 1,997 1,828 1,765 2,680 - 2,976
Book Value per Share		 $16.71 $16.87 $17.01 $17.42 $18.28 $18.76 $18.47 $19.00 $18.72 $18.52 $18.70
Tangible Book Value per Share		 $2.82 $3.75 $4.25 $5.11 $6.35 $7.19 $7.37 $8.32 $5.48 $6.41 $7.06
Total Capital		 958 974 981 1,005 1,054 1,083 1,061 1,064 1,061 1,093 1,077
Total Debt		 46 52 51 47 47 47 30 0.00 11 31 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -179 -219 -258 -300 -357 -406 -434 -523 -270 -278 -384
Capital Expenditures (CapEx)		 0.15 -0.04 0.25 0.06 0.20 0.21 0.33 0.46 0.13 0.43 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 7.52 0.11 -17 -18 -8.13 -13 -28 -70 -6.66 28 -27
Debt-free Net Working Capital (DFNWC)		 208 255 281 330 395 441 436 453 274 337 358
Net Working Capital (NWC)		 162 203 230 282 348 394 406 453 263 306 358
Net Nonoperating Expense (NNE)		 2.83 -2.36 -1.73 -2.83 -3.51 -2.89 4.65 -6.11 2.96 1.35 -3.54
Net Nonoperating Obligations (NNO)		 -179 -219 -258 -300 -357 -406 -434 -523 -270 -278 -384
Total Depreciation and Amortization (D&A)		 22 22 23 20 21 18 19 21 24 26 26
Debt-free, Cash-free Net Working Capital to Revenue		 1.23% 0.02% 0.00% 0.00% 0.00% -1.90% -4.16% -10.54% -0.98% - -3.42%
Debt-free Net Working Capital to Revenue		 34.02% 41.97% 0.00% 0.00% 0.00% 66.64% 65.24% 68.03% 40.28% - 46.04%
Net Working Capital to Revenue		 26.51% 33.40% 0.00% 0.00% 0.00% 59.48% 60.75% 68.03% 38.63% - 46.04%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.29) $0.02 $0.00 $0.36 $0.70 $0.28 ($0.21) $0.40 ($0.80) ($0.07) ($0.04)
Adjusted Weighted Average Basic Shares Outstanding		 54.61M 54.54M 54.80M 54.98M 55.15M 55.10M 55.86M 56.02M 56.55M 56.45M 57.65M
Adjusted Diluted Earnings per Share		 ($0.29) $0.04 $0.00 $0.36 $0.69 $0.27 ($0.21) $0.40 ($0.80) ($0.07) ($0.04)
Adjusted Weighted Average Diluted Shares Outstanding		 54.61M 55.51M 55.63M 55.72M 56.02M 55.96M 55.86M 56.64M 56.55M 56.45M 57.65M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 54.63M 0.00 54.97M 55.11M 55.22M 55.81M 55.99M 56.07M 57.34M 57.58M 58.04M
Normalized Net Operating Profit after Tax (NOPAT)		 5.38 -0.84 -2.17 14 34 13 -1.82 8.50 -42 9.68 -4.16
Normalized NOPAT Margin		 3.49% -0.51% -1.51% 8.19% 19.42% 7.26% -1.21% 5.14% -21.95% - -2.00%
Pre Tax Income Margin		 6.43% 0.60% 0.17% 15.63% 25.58% 15.15% -3.89% 10.07% -30.17% - -2.86%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%

Financials Breakdown Chart

Key Financial Trends

Here are the key takeaways for SUPERNUS PHARMACEUTICALS, INC. (SUPN) based on the last four years of quarterly statements available, focusing on cash flow, profitability, and the balance sheet. Items are shown with positives first, then neutrals, then negatives.

  • Revenue has trended higher in 2025, with Q4 2025 revenue of about $211.6 million, up from about $174.2 million in Q4 2024.
  • Gross margin remained strong in Q4 2025, with gross profit of roughly $188.6 million on revenue of $211.6 million (about 89% gross margin).
  • Operating cash flow has been positive in several 2025 quarters (e.g., Q2 2025: ≈$58.5 million; Q4 2025: ≈$19.9 million; Q1 2025: ≈$30.6 million), underscoring ongoing cash generation from core operations despite quarterly swings.
  • The balance sheet shows a solid capitalization: total assets around $1.42 billion and total equity around $1.05 billion in mid-2025, with long-term debt effectively zero.
  • The company held a healthy cash balance as of Q3 2025, with cash & equivalents around $151.4 million, supporting liquidity for operations and milestones.
  • In 2025, SUPN raised roughly $56 million via issuance of common equity across four quarters, improving liquidity but increasing share count (dilution potential).
  • Debt levels remain relatively modest: no long-term debt in recent periods, and only a small amount of short-term debt, indicating a low-leverage balance sheet.
  • Investing activities show ongoing cash outflows as the company continues to invest in assets and investments (e.g., sizable net cash outflows in 2025 from continuing investing activities), which is typical for a growth-focused pharma company.
  • Earnings per quarter show variability: Q2 2025 was net income positive, while Q3 2025 and Q4 2025 were negative, highlighting earnings volatility on a quarterly basis.
  • Net change in cash in Q4 2025 was negative at about −$22.9 million, indicating a quarterly cash decrease that could pressure liquidity unless offset by financing activity or operating cash flow in subsequent quarters.
05/26/26 02:39 AM ETAI Generated. May Contain Errors.

Supernus Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Supernus Pharmaceuticals' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Supernus Pharmaceuticals' net income appears to be on a downward trend, with a most recent value of -$38.55 million in 2025, falling from $13.94 million in 2015. The previous period was $73.87 million in 2024. Find out what analysts predict for Supernus Pharmaceuticals in the coming months.

Supernus Pharmaceuticals' total operating income in 2025 was -$62.28 million, based on the following breakdown:
  • Total Gross Profit: $644.39 million
  • Total Operating Expenses: $706.67 million

Over the last 10 years, Supernus Pharmaceuticals' total revenue changed from $147.47 million in 2015 to $718.95 million in 2025, a change of 387.5%.

Supernus Pharmaceuticals' total liabilities were at $390.93 million at the end of 2025, a 17.6% increase from 2024, and a 288.5% increase since 2015.

In the past 10 years, Supernus Pharmaceuticals' cash and equivalents has ranged from $33.50 million in 2015 to $288.64 million in 2020, and is currently $128.45 million as of their latest financial filing in 2025.

Over the last 10 years, Supernus Pharmaceuticals' book value per share changed from 1.80 in 2015 to 18.52 in 2025, a change of 929.3%.


Related Companies

Financial statements for NASDAQ:SUPN last updated on 5/8/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
The S-1 just dropped. 22 days left.
The SpaceX S-1 is now public - $18.7 billion in revenue, a $75 billion raise, and a June 12 Nasdaq listing con...
Behind the Markets | Sponsoredtc pixel
My crisis of conscience
Emmet Savage - named in Irish America's Wall Street 50 as one of the most successful investors in the world - ...
Porter & Company | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel
Your book attached
Bill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...
Profits Run | Sponsoredtc pixel
Trump Admin to Pump $1 Billion into this “Off-the-Radar” AI Stock
The U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...
InvestorPlace | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...
Eagle Publishing | Sponsoredtc pixel